https://www.selleckchem.com/pr....oducts/pkc-theta-inh
4%, 84.9%, and 74.9%, respectively. The 1-, 3-, and 5-year disease-free survival (DFS) rates were 77.9%, 47%, and 38.9%, respectively. S-CLM located in the left liver ( =.04), S-CLM KRAS mutation ( .01), and extra-hepatic recurrence ( .01) were identified as independent poor risk factors for overall survival (OS); the OS and DFS were comparable in patients with surgical procedure or percutaneous MWA. In eligible S-CLM cases, percutaneous MWA seems to be as oncologically efficient as surgical resection and should be i
Like
Comment
Share
